Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder involving nerves and muscles that results in significant muscle weakness. It is often associated with certain types of cancer or other autoimmune disorders. It is caused by faulty nerve cells that fail to release sufficient amounts of acetylcholine, the chemical essential for the conduction of impulses between nerves and muscles. There are a number of treatments available for the disorder, but serious complications are possible.
This report contains market size and forecasts of Lambert-Eaton Myasthenic Syndrome Treatment in Global, including the following market information:
Global Lambert-Eaton Myasthenic Syndrome Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Lambert-Eaton Myasthenic Syndrome Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Potassium Channel Blockers (Amifampridine) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Lambert-Eaton Myasthenic Syndrome Treatment include Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc. and Mitsubishi Pharma Corporation. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lambert-Eaton Myasthenic Syndrome Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lambert-Eaton Myasthenic Syndrome Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Lambert-Eaton Myasthenic Syndrome Treatment Market Segment Percentages, by Type, 2021 (%)
Potassium Channel Blockers (Amifampridine)
Cholinesterase Inhibitor (Pyridostigmine)
Immune Therapy
Intravenous Immunoglobulin
Plasmapheresis
Global Lambert-Eaton Myasthenic Syndrome Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Lambert-Eaton Myasthenic Syndrome Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Ambulatory Surgical Centers
Others
Global Lambert-Eaton Myasthenic Syndrome Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Lambert-Eaton Myasthenic Syndrome Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lambert-Eaton Myasthenic Syndrome Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Lambert-Eaton Myasthenic Syndrome Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan, Plc.
Biomarin Pharmaceutical, Inc.
Catalyst Pharmaceuticals, Inc.
F. Hoffman-La Roche Ltd.
GlaxoSmithkline, Plc.
Jacobus Pharmaceutical Company, Inc.
Kawasumi Laboratories, Inc.
Merck & Co., Inc.
Mitsubishi Pharma Corporation